z-logo
open-access-imgOpen Access
Rapidly Progressive Glomerulonephritis with Delayed Appearance of Anti-Glomerular Basement Membrane Antibody Successfully Treated with Multiple Courses of Steroid Pulse Therapy
Author(s) -
Satoshi Toyota,
Masahiro Eriguchi,
Shoko Hasegawa,
Kenji Ueki,
Yuta Matsukuma,
Akihiro Tsuchimoto,
Kiichiro Fujisaki,
Kumiko Torisu,
Kazuhiko Tsuruya,
Toshiaki Nakano,
Takanari Kitazono
Publication year - 2019
Publication title -
case reports in nephrology and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.278
H-Index - 7
ISSN - 2296-9705
DOI - 10.1159/000499401
Subject(s) - rapidly progressive glomerulonephritis , medicine , glomerulonephritis , renal biopsy , glomerular basement membrane , renal function , antibody , proteinuria , basement membrane , plasmapheresis , gastroenterology , immunology , kidney , pathology
Patients with anti-glomerular basement membrane (GBM) antibody glomerulonephritis typically exhibit rapidly progressive glomerulonephritis (RPGN). The renal outcome as well as the prognosis of this disease is worse than other forms of RPGN such as those from microscopic polyangiitis. Therefore, early therapeutic intervention is essential to improve its prognosis. One month before referral to our hospital, a 54-year-old female attended another hospital because of macrohematuria. At that time, she had proteinuria and macrohematuria with normal renal function, was negative for anti-GBM antibodies, and was diagnosed with chronic glomerulonephritis. A month later when she was admitted to our hospital, she showed renal insufficiency and was positive for anti-GBM antibodies. Immediately after recognizing the anti-GBM antibody status, plasma exchange and the first course of steroid pulse therapy was started. After 5 days of therapy, renal biopsy confirmed severe crescentic glomerulonephritis in which all the observed glomeruli were involved with cellular crescents. Despite this, she survived without end-stage renal disease after three courses of steroid pulse therapy and seven sessions of plasma exchange. This favorable outcome reflects the repeated analysis of anti-GBM antibodies within a very short period and the rapid therapeutic intervention in addition to the intensive immunosuppressive therapies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom